β-Arrestin2 regulates RANKL and Ephrins gene expression in response to bone remodeling in mice

Journal of Bone and Mineral Research

Volumn 24, Issue 5, 2009, Pages 775-784

  Pierroz, Dominique D ^a,d   Rufo, Anna ^b   Biancht, Estelle N ^a   Glatt, Vaida ^c   Capulli, Mattia ^b   Rucci, Nadia ^b   Cavat, Fanny ^a   Rizzoli, René ^a   Teti, Anna ^b   Bouxsein, Mary L ^c   Ferrari, Serge L ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

arrestin2; Bone remodeling; Ephrin; Low calcium diet; RANKL

Indexed keywords

BETA ARRESTIN 2; EPHRIN; EPHRIN RECEPTOR; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; BONE REMODELING; BONE TURNOVER; CANCELLOUS BONE; CELL ACTIVITY; CELL MATURATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; WILD TYPE;

ANIMALS; ARRESTINS; BIOLOGICAL MARKERS; BONE AND BONES; BONE MARROW CELLS; BONE REMODELING; CALCIUM, DIETARY; CELLS, CULTURED; COCULTURE TECHNIQUES; EPHRINS; GENE EXPRESSION REGULATION; GENE SILENCING; MICE; ORGAN SIZE; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OVARIECTOMY; PARATHYROID HORMONE; RANK LIGAND; RECEPTORS, EPH FAMILY;

EID: 65949091145     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.081237     Document Type: Article

References (38)

1. Zaidi M 2007 Skeletal remodeling in health and disease. Nat Med 13:791-801.
2. Kostenuik PJ. Ferrari S, Pierroz D, Bouxsein M, Morony S, Warmington KS, Adamu S, Geng Z, Grisanti M, Shalhoub V, Martin S, Biddlecome G, Shimamoto G, Boone T, Shen V, Lacey D 2007 Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone. J Bone Miner Res 22:1534-1547.
3. Qin L, Raggatt LJ, Partridge NC 2004 Parathyroid hormone: A double-edged sword for bone metabolism. Trends Endo-crinol Metab 15:60-65.
4. Ledger GA, Burritt MF, Kao PC, O'Fallon WM, Riggs BL, Khosla S 1994 Abnormalities of parathyroid hormone secretion in elderly women that are reversible by short term therapy with 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 79:211-216.
5. Wada T, Nakashima T, Hiroshi N, Penninger JM 2006 RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12:17-25.
6. Shevde NK, Bendixen AC, Dienger KM, Pike JW 2000 Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA 97:7829-7834.
7. Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA 2004 PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 19:235-244.
8. Stilgren LS, Rettmer E, Eriksen EF, Hegedus L, Beck-Nielsen H, Abrahamsen B 2004 Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRN A levels in primary hyperparathyroidism: Effect of parathy-roidectomy and association with bone metabolism. Bone 35:256-265.
9. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL 2003 Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111:1221-1230.
10. Zhao C, Irie N, Takada Y. Shimoda K, Miyamoto T, Nishiwaki T, Suda T, Matsuo K 2006 Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 4:111-121.
11. Allan EH, Hausler KD, Wei T, Gooi JH, Quinn JM, Crimeen-Irwin B, Pompolo S, Sims NA, Gillespie MT, Onyia JE, Martin TJ 2008 EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res 23:1170-1181.
12. Bisello A, Chorev M, Rosenblatt M, Monticelli L, Mierke DF, Ferrari SL 2002 Selective ligand-induced stabilization of active and desensitized parathyroid hormone type 1 receptor conformations. J Biol Chem 277:38524-38530.
13. Ferrari SL, Behar V. Chorev M, Rosenblatt M, Bisello A 1999 Endocytosis of ligand-human parathyroid hormone receptor 1 complexes is protein kinase C-dependent and involves beta-arrestin2. Real-time monitoring by fluorescence microscopy. J Biol Chem 274:29968-29975.
14. Ferrari SL, Bisello A 2001 Cellular distribution of constitu-tively active mutant parathyroid hormone (PTH)/PTH-related protein receptors and regulation of cyclic adenosine 3′,5′-monophosphate signaling by beta-arrestin2. Mol Endocrinol 15:149-163.
15. Rey A, Manen D. Rizzoli R, Caverzasio J. Ferrari SL 2006 Proline-rich motifs in the parathyroid hormone (PTH)/PTH-related protein receptor C terminus mediate scaffolding of c-Src with beta-arrestin2 for ERK1/2 activation. J Biol Chem 281:38181-38188.
16. Chen W, Ren XR, Nelson CD, Barak LS, Chen JK. Beachy PA, de Sauvage F, Lefkowitz RJ 2004 Activity-dependent internalization of smoothened mediated by beta-arrestin 2 and GRK2. Science 306:2257-2260.
17. Chen W, ten Berge D, Brown J, Ahn S. Hu LA, Miller WE, Caron MG, Barak LS. Nusse R, Lefkowitz RJ 2003 Dishevelled 2 recruits beta-arrestin 2 to mediate Wnt5A-stimulated endocytosis of Frizzled 4. Science 301:1391-1394.
18. Chen W, Kirkbride KC, How T, Nelson CD, Mo J, Frederick JP, Wang XF, Lefkowitz RJ, Blobe GC 2003 Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling. Science 301:1394-1397.
19. Lefkowitz RJ, Rajagopal K, Whalen EJ 2006 New roles for beta-arrestins in cell signaling: Not just for seven-transmembrane receptors. Mol Cell 24:643-652.
20. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT 1999 Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286:2495-2498.
21. Bradaia A, Berton F, Ferrari S, Luscher C 2005 Beta-arrestin2, interacting with phosphodiesterase 4, regulates synaptic release probability and presynaptic inhibition by opioids. Proc Natl Acad Sci USA 102:3034-3039.
22. Jiang B, Shi Y, Li H, Kang L, Ma L 2006 Decreased morphine analgesia in rat overexpressing beta-arrestin 2 at periaqueductal gray. Neurosci Lett 400:150-153.
23. Walker JK, Fong AM, Lawson BL, Savov JD, Patel DD, Schwartz DA, Lefkowitz RJ 2003 Beta-arrestin-2 regulates the development of allergic asthma. J Clin Invest 112:566-574.
24. Ferrari SL, Pierroz DD, Glatt V, Goddard DS, Bianchi EN. Lin FT, Manen D, Bouxsein ML 2005 Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2. Endocrinology 146:1854-1862.
25. Bouxsein ML, Pierroz DD, Glatt V, Goddard DS, Cavat F. Rizzoli R, Ferrari SL 2005 beta-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice. J Bone Miner Res 20:635-643.
26. Syed F, Khosla S 2005 Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun 328:688-696.
27. Lotinun S, Sibonga JD, Turner RT 2002 Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression. Endocrine 17:29-36.
28. David JP, Neff L, Chen Y, Rincon M, Home WC, Baron R 1998 A new method to isolate large numbers of rabbit osteo-clasts and osteoclast-like cells: Application to the characterization of serum response element binding proteins during osteoclast differentiation. J Bone Miner Res 13:1730-1738.
29. Teti A, Taranta A, Villanova I, Recchia I, Migliaccio S 1999 Osteoclast isolation: New developments and methods. J Bone Miner Res 14:1251-1252.
30. Caselli G, Mantovanini M, Gandolfi CA, Allegretti M, Fiorentino S. Pellegrini L, Melillo G, Bertini R, Sabbatini W, Anacardio R, Clavenna G, Sciortino G. Teti A 1997 Tartronates: A new generation of drugs affecting bone metabolism. J Bone Miner Res 12:972-981.
31. Marzia M, Sims N A, Voit S, Migliaccio S, Taranta A, Bernardini S, Faraggiana T, Yoneda T, Mundy GR, Boyce BF, Baron R, Teti A 2000 Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 151:311-320.
32. Hildebrand T, Ruegsegger P 1997 Quantification of Bone Microarchitecture with the Structure Model Index. Comput Methods Biomech Biomed Engin 1:15-23.
33. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM. Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610.
34. Witherow DS. Garrison TR, Miller WE. Lefkowitz RJ 2004 beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha. Proc Natl Acad Sci USA 101:8603-8607.
35. Borah B. Dufresne TE, Ritman EL, Jorgensen SM, Liu S, Chmielewski PA, Phipps RJ. Zhou X, Sibonga JD, Turner RT 2006 Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: Sequential triple biopsy studies with micro-computed tomography. Bone 39:345-352.
36. Fu Q, Jilka RL, Manolagas SC, O'Brien CA 2002 Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem 277:48868-48875.
37. Kondo H, Guo J, Bringhurst FR 2002 Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. J Bone Miner Res 17:1667-1679.
38. Kim S, Yamazaki M, Shevde NK, Pike JW 2007 Transcrip-tional control of receptor activator of nuclear factor-kappaB ligand by the protein kinase A activator forskolin and the transmembrane glycoprotein 130-activating cytokine, oncos-tatin M, is exerted through multiple distal enhancers. Mol Endocrinol 21:197-214.